ASCENT
Live / Registered — Registered (as of 23 Dec 2025)
What this means for you
Registered since 23 Dec 2025. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 23 Dec 2031: the §8 declaration of use).
Record
- Serial number
- 90133732
- Registration number
- 8078650
- Mark type
- Word mark
- Filed
- 24 Aug 2020
- Published for opposition
- 18 Mar 2025
- Registered
- 23 Dec 2025
- Next maintenance filing
- §8 declaration of use, due by 23 Dec 2031 (grace period to 23 Jun 2032)
- Attorney of record
- William R. Samuels
Goods and services
- Class 042 — Scientific and technological services: Medical and scientific research, namely, conducting clinical trials for others, all the above for gene therapy, namely for use in the treatment of wet age-related macular degeneration (AMD) using subretinal delivery
Owner
- RegenxBio Inc., Rockville, MD, US
- RegenxBio Inc., Rockville, MD, US
- RegenxBio Inc., Rockville, MD, US
Board proceedings on this mark
- Ex Parte Appeal No. 90133732 — RegenxBio Inc., filed 06 Dec 2024 (Terminated)
Prosecution history
- 23 Dec 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 23 Dec 2025 — REGISTERED-PRINCIPAL REGISTER
- 04 Dec 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 04 Dec 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 03 Dec 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 09 Jun 2025 — USE AMENDMENT FILED
- 02 Dec 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 09 Jun 2025 — TEAS STATEMENT OF USE RECEIVED
- 13 May 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 18 Mar 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 18 Mar 2025 — PUBLISHED FOR OPPOSITION
- 12 Mar 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 20 Feb 2025 — EXPARTE APPEAL TERMINATED
- 20 Feb 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 Jan 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED